TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9172085

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 131

Group type: COMPARATOR
Intervention: Unvaccinated
Number of subjects: 131
Study: 1426866

Group type: EXPERIMENTAL
Intervention: Bismuth
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Bismuth plus antibiotics
Number of subjects: 84

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: H. pylori eradicated
Number of subjects: 84

Group type: COMPARATOR
Intervention: H. pylori not eradicated
Number of subjects: 84
Study: 3913728

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 431

Group type: COMPARATOR
Intervention: Control
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Warfarin and Control
Number of subjects: 431
Study: 3304625

Group type: EXPERIMENTAL
Intervention: Intensive course of chemotherapy consisting of vincristine, procarbazine and methotrexate, followed by citrovorum factor rescue
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Reduced radiotherapy to CNS areas outside the primary tumour site by 10 Gy
Number of subjects: 350
Study: 29022212

Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 4-mg tablet under fed conditions (high-calorie and high-fat breakfast)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saroglitazar magnesium 4-mg tablet under fasting conditions
Number of subjects: 54
Study: 27054695

Group type: EXPERIMENTAL
Intervention: CRAE (central retinal artery equivalent) measurement
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: CRVE (central retinal vein equivalent) measurement
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Association of CRAE with macular ganglion cell layer thickness
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Association of CRVE with macular retinal thickness
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Association of CRVE with retinal nerve fibre layer thickness at the optic disc
Number of subjects: 440
Study: 24727897

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation in a shortened position (CT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation in a neutral position (nCT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 15
Study: 23672318

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (0.25 mg/kg bupivacaine 0.5%)
Number of subjects: 100

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 100
Study: 20578393

Group type: EXPERIMENTAL
Intervention: Explanatory clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pragmatic clinical trials
Number of subjects: 0
Study: 18793342

Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Buspirone 40 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Buspirone 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Buspirone 5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 10
Study: 16884504

Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP) mode
Number of subjects: 129

Group type: COMPARATOR
Intervention: DDD/R mode
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP) mode in patients with SND
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP) mode in patients with AVB
Number of subjects: 129
Study: 12591053

Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU) and Vitamin C (1000 mg) supplementation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 10943585

Group type: EXPERIMENTAL
Intervention: Thrombolytic agent (urokinase or streptokinase), n = 12
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heparin, n = 11
Number of subjects: 40
Study: 8765432

Group type: EXPERIMENTAL
Intervention: UFT plus leucovorin (30 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: UFT alone (400 mg/day)
Number of subjects: 26
Study: 2013559

Group type: EXPERIMENTAL
Intervention: Ketotifen treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (5 normal volunteers)
Number of subjects: 30
Study: 6148878

Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nadolol 160 mg/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 30876431

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 30 s) combined with upper limb physical therapy (20 min passive movement + 20 min active mini-bike) for 10 sessions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS (current stimulation for 30 s) combined with upper limb physical therapy (20 min passive movement + 20 min active mini-bike) for 10 sessions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA) combined with upper limb physical therapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS combined with upper limb physical therapy.
Number of subjects: 0
Study: 29944604

Group type: EXPERIMENTAL
Intervention: Ketone ester (KE) supplement (750 mg·kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study: 27142443

Group type: EXPERIMENTAL
Intervention: 8-session group intervention
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205
Study: 23707139

Group type: EXPERIMENTAL
Intervention: Weights (3 repetition‐maximum [RM] bench press and squat)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sprint (5 × 40 m)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (rested)
Number of subjects: 18
Study: 22845718

Group type: EXPERIMENTAL
Intervention: Misgav Ladach technique (Group 1)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Traditional (Pfannenstiel) technique (Group 2)
Number of subjects: 112
Study: 20927781

Group type: EXPERIMENTAL
Intervention: GDC-0449 (hedgehog pathway inhibitor), once per day continuous therapy, oral administration
Number of subjects: 3
Study: 18830041

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study: 16418556

Group type: EXPERIMENTAL
Intervention: Abdominal breathing training using biofeedback (once a week for 4 weeks)
Number of subjects: 25
Study: 11155152

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) at 3 MU thrice weekly (TIW) for 12 months
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) at 6 MU TIW
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) at 3 MU TIW
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) in cirrhotic patients
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) for acute hepatitis C
Number of subjects: 66
Study: 9542555

Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Propacetamol + PCA morphine
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 7522977

Group type: EXPERIMENTAL
Intervention: 0.75 micrograms.kg‐1 pentamorphone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 1 microgram.kg‐1 pentamorphone
Number of subjects: 64

Group type: COMPARATOR
Intervention: 5 micrograms.kg‐1 fentanyl
Number of subjects: 64

Group type: COMPARATOR
Intervention: 7.5 micrograms.kg‐1 fentanyl
Number of subjects: 64
Study: 3045033

Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2 interferon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31466693

Group type: EXPERIMENTAL
Intervention: Guided self-help modality intervention delivered by psychologists
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Modified counsellor-led problem-solving intervention implemented by less experienced counsellors
Number of subjects: 84
Study: 30648919

Group type: EXPERIMENTAL
Intervention: PCV15 Formulation A
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: PCV15 Formulation B
Number of subjects: 690

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 690
Study: 26967591

Group type: EXPERIMENTAL
Intervention: 18‐mmHg graduated stockings
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 23‐mmHg graduated stockings
Number of subjects: 40

Group type: COMPARATOR
Intervention: No hosiery
Number of subjects: 40
Study: 26054135

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion treatment applied to specific acupuncture points (Shenque, Zhongji, Guanyuan, Qihai, Zigong, Xuebai) for 3 sessions until transfer time.
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group with no acupuncture and moxibustion intervention.
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion treatment.
Number of subjects: 114
Study: 23681030

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone, 8 mg
Number of subjects: 328

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 328
Study: 21685111

Group type: EXPERIMENTAL
Intervention: Intranasal DEX 1 µg kg(‐1) (Group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (Group P)
Number of subjects: 60
Study: 19214556

Group type: EXPERIMENTAL
Intervention: Beta-alanine supplementation (6.4 g day(-1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PLG)
Number of subjects: 14
Study: 17872930

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 15086482

Group type: EXPERIMENTAL
Intervention: Albumin synthesis measurement after serum albumin decline
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Measurement of inflammatory markers (IL-6, CRP, alpha1AG, ceruloplasmin)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Equilibrated normalized protein catabolic rate (enPCR) measurement
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Serum albumin concentration measurement
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Overall analysis of all patients
Number of subjects: 79
Study: 11471851

Group type: EXPERIMENTAL
Intervention: Proprietary omeprazole (20 ‐ 40 mg/day depending on age) + metronidazole (30 ‐ 40 mg/kg per day) + amoxycillin (750 mg/day)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Generic omeprazole (20 ‐ 40 mg/day) + metronidazole (30 ‐ 40 mg/kg per day) + amoxycillin (750 mg/day)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily) + metronidazole (30 ‐ 40 mg/kg per day) + amoxycillin (750 mg/day)
Number of subjects: 106
Study: 9693998

Group type: EXPERIMENTAL
Intervention: Biographical Personality Interview (BPI)
Number of subjects: 179
Study: 8163736

Group type: EXPERIMENTAL
Intervention: Starchy food products, 12-15 times a day, in addition to the normal diet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sucrose products, 12-15 times a day, in addition to the normal diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control period (no addition of test products to the normal diet)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10% sucrose mouthrinse
Number of subjects: 8
Study: 3170784

Group type: EXPERIMENTAL
Intervention: Sign-alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Speech-alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Simultaneous communication
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alternating between speech and sign
Number of subjects: 60
Study: 28843588

Group type: EXPERIMENTAL
Intervention: High religiosity group listening to non-consensual kiss scenario
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Low religiosity group listening to non-consensual kiss scenario
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: High religiosity group listening to consensual kiss scenario
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Low religiosity group listening to consensual kiss scenario
Number of subjects: 92

Group type: COMPARATOR
Intervention: High religiosity group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Low religiosity group
Number of subjects: 92
Study: 26395410

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Operative treatment for femoral deformities
Number of subjects: 10

Group type: COMPARATOR
Intervention: Operative treatment for acetabular deformities
Number of subjects: 10

Group type: COMPARATOR
Intervention: Labral refixation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Capsular closure
Number of subjects: 10
Study: 26009922

Group type: EXPERIMENTAL
Intervention: Guided bone regeneration (GBR) with recombinant human platelet‐derived growth factor‐BB (rhPDGF‐BB) incorporated into a beta‐tricalcium phosphate (β‐TCP)/hydroxyapatite (HA) carrier
Number of subjects: 30

Group type: COMPARATOR
Intervention: Autogenous bone block grafting
Number of subjects: 30
Study: 23143753

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hemodialysis
Number of subjects: 24
Study: 21676892

Group type: COMPARATOR
Intervention: 0.5% ropivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine mixed with dexamethasone 8 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine mixed with dexamethasone 8 mg
Number of subjects: 0
Study: 19706108

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser therapy with topical 1% pimecrolimus cream twice daily (group A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Excimer laser therapy twice per week (group B)
Number of subjects: 49
Study: 16425615

Group type: EXPERIMENTAL
Intervention: Higher education level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reading books
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doing crosswords
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Presurgery condition
Number of subjects: 0
Study: 14704801

Group type: EXPERIMENTAL
Intervention: Simultaneous explosive strength training (11-week duration)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19
Study: 11306521

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/d (n=35)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (n=17)
Number of subjects: 52
Study: 7745014

Group type: EXPERIMENTAL
Intervention: 75 IU human urinary FSH (uFSH) administered subcutaneously (sc)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 150 IU human urinary FSH (uFSH) administered subcutaneously (sc)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Multidose administration of either 75 or 150 IU uFSH, sc
Number of subjects: 10
Study: 2244794

Group type: EXPERIMENTAL
Intervention: High delta sleep ratio
Number of subjects: 74

Group type: COMPARATOR
Intervention: Low delta sleep ratio
Number of subjects: 74
Study: 343969

Group type: EXPERIMENTAL
Intervention: Synthetic nitrogen analog of tetrahydrocannabinol (NIB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50 mg codeine phosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50 mg secobarbital
Number of subjects: 0
Study: 31628490

Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg monthly followed by placebo (n=19)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Romosozumab following denosumab (n=16)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Initial treatment with Romosozumab 210 mg monthly
Number of subjects: 167
Study: 29102158

Group type: EXPERIMENTAL
Intervention: N'Durance® Dimer Flow (ND)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Filtek™ Supreme XTE Flow (FS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both ND and FS
Number of subjects: 50
Study: 25661462

Group type: EXPERIMENTAL
Intervention: Dry needling treatment of a single active MTrP
Number of subjects: 56
Study: 23382539

Group type: EXPERIMENTAL
Intervention: Cardiovascular polypill (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12.5 mg) taken in the evening
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cardiovascular polypill taken in the morning
Number of subjects: 75

Group type: COMPARATOR
Intervention: Identically dosed agents in separate pills taken at different time points during the day
Number of subjects: 75
Study: 22871107

Group type: EXPERIMENTAL
Intervention: Self-management support program (SMP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual community care (Control)
Number of subjects: 160
Study: 20129531

Group type: EXPERIMENTAL
Intervention: Pexelizumab
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 17879926

Group type: EXPERIMENTAL
Intervention: Simplification strategy using a boosted protease inhibitor (PI) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simplification strategy
Number of subjects: 0
Study: 16252435

Group type: EXPERIMENTAL
Intervention: Coin in the Hand Test (CIH)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Wechsler Mental Control Test (MCT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rey I 5‐Item Test (RIT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Autobiographical Memory Index (AMI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group instructed to simulate head injury performance (N = 40)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group instructed to do their best (N = 40)
Number of subjects: 40
Study: 12014939

Group type: EXPERIMENTAL
Intervention: Telephone access to MRI requests
Number of subjects: 414

Group type: COMPARATOR
Intervention: Written access to MRI requests
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Practice-based seminar for guideline dissemination
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Practice-specific audit feedback for guideline dissemination
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Both seminar and feedback for guideline dissemination
Number of subjects: 414

Group type: COMPARATOR
Intervention: Control group (no seminar or feedback) for guideline dissemination
Number of subjects: 414
Study: 10469040

Group type: EXPERIMENTAL
Intervention: 180 mg of oral terfenadine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 120 microg of inhaled ipratropium bromide
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 8681154

Group type: EXPERIMENTAL
Intervention: Group 20 (20 reps of 20% of 1 RM)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Group 40 (10 reps of 40% of 1 RM)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Group 60 (7 reps of 60% of 1 RM)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (aerobic training only)
Number of subjects: 57
Study: 1852278

Group type: EXPERIMENTAL
Intervention: Ramco latex agglutination test
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (stable medical problems)
Number of subjects: 51
Study: 6341632

Group type: EXPERIMENTAL
Intervention: Chymopapain (Chymodiactin)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (after failure)
Number of subjects: 108
Study: 30784555

Group type: EXPERIMENTAL
Intervention: Prasugrel (3·75 mg/day)
Number of subjects: 3747

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/day)
Number of subjects: 3747

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 3747

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 3747
Study: 28727578

Group type: EXPERIMENTAL
Intervention: Greater physical activity level at baseline
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Engaging in 1 additional hour per day of moderate activity
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Greater physical activity level at baseline (after controlling for other variables)
Number of subjects: 103
Study: 26729431

Group type: EXPERIMENTAL
Intervention: 4 Gy × 5
Number of subjects: 203

Group type: COMPARATOR
Intervention: 3 Gy × 10
Number of subjects: 203
Study: 25115285

Group type: EXPERIMENTAL
Intervention: Avena Rhealba(®) extract and hyaluronic acid (Product A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Reference product B
Number of subjects: 21

Group type: COMPARATOR
Intervention: Reference product C
Number of subjects: 21

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All three products (A, B, C)
Number of subjects: 21
Study: 22501080

Group type: EXPERIMENTAL
Intervention: Acoustic simulations of unilateral CI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bimodal (CI+HA) hearing
Number of subjects: 0
Study: 19575814

Group type: EXPERIMENTAL
Intervention: Coronary artery by-pass grafting without the use of cardiopulmonary by-pass (CPB) and aortic cross-clamping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery by-pass grafting with the use of cardiopulmonary by-pass (CPB) and aortic cross-clamping
Number of subjects: 0
Study: 18093949

Group type: EXPERIMENTAL
Intervention: Left hemisphere (LH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Right hemisphere (RH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left-handed subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI)
Number of subjects: 0
Study: 15577620

Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: HAART alone (Control)
Number of subjects: 21
Study: 11161546

Group type: EXPERIMENTAL
Intervention: Formula containing n-6 and n-3 LCP from purified phospholipids (LCP-F)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional formula (F)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 34
Study: 9679818

Group type: EXPERIMENTAL
Intervention: Thymoglobulin (1.5 mg/kg/day for 7-14 days)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Atgam (15 mg/kg/day for 7-14 days)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 163

Group type: COMPARATOR
Intervention: Atgam
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Thymoglobulin and Atgam
Number of subjects: 163